SynthesisDiabetes/metabolism research and reviews2026
Epidemiology of Diabetes Mellitus in Patients With Psoriatic Arthritis: Current Evidence.
Synthesis in Diabetes/metabolism research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
aimsDiabetes mellitus (DM) is a common comorbidity of psoriatic arthritis (PsA); however, its global prevalence and the impact of treatment exposure remain unclear. This study aimed to assess the global prevalence of DM in patients with PsA using different subgroup analyses. MATERIALS AND
methodsA systematic search of PubMed, Embase, the Cochrane Library and the Web of Science was performed from inception until February 2025 for observational studies reporting the prevalence or incidence of DM in PsA patients. Random-effects models were applied to pool estimates, and subgroup, meta-regression, and sensitivity analyses were conducted to explore heterogeneity. Publication bias was evaluated using the Egger's test and the trim-and-fill method.
resultsSixty-three studies, including 293,582 patients with PsA, were analysed. Patients with PsA included in this study were divided into treatment-disclosed and non-treatment-disclosed groups. DM overall prevalence in patients with PsA was 13.84% in the non-treatment-disclosed population and 13.50% in the treatment-disclosed cohort. Geographically, the comorbidity prevalence rates were higher in South America (37.98%) and Asia (16.76%) than in Europe (12.81%) and North America (12.38%) in the non-treatment-disclosed population. In the treatment-disclosed population, prevalence was also highest in South America (28.13%), followed by Asia (18.30%). Meta-regression analysis identified age, type of DM, region, and study design as contributors to heterogeneity. Evidence of small-study effects was detected in the T2DM subgroup and cohorts receiving systemic therapy plus biologics.
conclusionsSubgroup analysis shows that the prevalence of DM is associated with the type of study and the region in which the patients were located. These findings support routine metabolic screening for PsA and highlight the need for longitudinal studies to track disease activity, treatment patterns, and metabolic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.